This site is intended for Healthcare professionals only.

Samsung Bioepis says FDA to review Herceptin copy

Samsung Bioepis says FDA to review Herceptin copy

SEOUL: South Korea’s Samsung Bioepis Co Ltd said on Wednesday the U.S. Food and Drug Administration (FDA) has accepted for review its copy of Swiss drugmaker Roche’s blockbuster breast cancer drug Herceptin for potential approval.

Samsung Bioepis said in a statement that if approved, its version of Herceptin will be commercialized in the United States by Merck, known as MSD outside of the United States and Canada.

Samsung Bioepis’ Herceptin copy, called Ontruzant, was the first biosimilar version of the drug to be approved in Europe.

Mylan NV’s Herceptin biosimilar was the first biosimilar approved in the United States to treat breast or stomach cancer.

Herceptin is one of the world’s most successful antibody drugs, generating global sales of 6.78 billion Swiss francs ($6.7 billion) in 2016 for Roche.

(Reporting by Joyce Lee; Editing by Stephen Coates)

The following two tabs change content below.
Ruby Khatun

Ruby Khatun

Ruby Khatun joined Medical Dialogue as Reporter in 2016. She covers all the business news in different categories. She also covers all the updates in Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a post graduate from Jamia Hamdard. She can be contacted at Contact no. 011-43720751

0 comment(s) on Samsung Bioepis says FDA to review Herceptin copy

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted